Demographic diversity of participants in Pfizer sponsored clinical trials in the United States.

The approval of new medicinal agents requires robust efficacy and safety clinical trial data demonstrated to be applicable to population subgroups. Limited data have previously been reported by drug sponsors on the topic of clinical trial diversity. In order to establish a baseline of diversity in our clinical trials that can be used by us and other sponsors, an analysis of clinical trial diversity was conducted covering race, ethnicity, sex, and age. This analysis includes Pfizer interventional clinical trials that initiated enrollment between 2011 through 2020. The data set comprises 213 trials with 103,103 US participants. The analysis demonstrated that overall trial participation of Black or African American individuals was at the US census level (14.3% vs 13.4%), participation of Hispanic or Latino individuals was below US census (15.9% vs 18.5%), and female participation was at US census (51.1% vs 50.8%). The analysis also examined the percentage of trials that achieved racial and ethnic distribution levels at or above census levels. Participant levels above census were achieved in 56.1% of Pfizer trials for Black or African American participants, 51.4% of trials for White participants, 16.0% of trials for Asian participants, 14.2% of trials for Native Hawaiian and Pacific Islander participants, 8.5% of trials for American Indian and Alaska Native participants, and 52.3% of trials for Hispanic or Latino participants. The results presented here provide a baseline upon which we can quantify the impact of our ongoing efforts to improve racial and ethnic diversity in clinical trials.

Inactivation of Ran1/Pat1 kinase bypasses the requirement for high-level expression of mei2 during fission yeast meiosis.

Ran1/Pat1 kinase and cAMP-dependent protein kinase (PKA) regulate sexual differentiation in Schizosaccharomyces pombe. A reduction in the activity of both enzymes is a prerequisite for meiosis. Together, PKA and Pat1 control the level of expression of the Mei2 RNA-binding protein. Pat1 further regulates the activity of Mei2 by phosphorylation. Phosphorylation inactivates Mei2 by interfering with its cellular localization and by causing degradation of the protein via the ubiquitin-proteasome pathway. The inhibitor of Pat1, Mei3, is found only in diploid cells undergoing meiosis. Expression of mei3 is sufficient to induce meiosis. Here, we examine the relationship between Pat1, PKA and Mei3. We demonstrate that Mei3 is an in vitro substrate for PKA. Using site-specific mutagenesis, the major PKA phosphorylation site is identified. In vivo assays indicate that phosphorylation of Mei3 by PKA does not significantly alter the ability of the inhibitor to regulate Pat1. Although it does not function as an inhibitor for PKA, ectopic expression of Mei3 causes cells containing high PKA levels to undergo meiosis. Expression of various mei3 alleles in cells containing unregulated PKA activity shows that the ability to undergo meiosis correlates with Pat1 activity. Notably, induced levels of mei2 are not a prerequisite for meiotic differentiation, as previously thought. The implications of this result to developmental regulation are discussed.